AstraZeneca: FDA Approves Lumoxiti for Hairy Cell Leukemia
September 14 2018 - 2:42AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug
Administration approved its drug Lumoxiti for patients with hairy
cell leukemia who had received other treatment previously.
The U.K. drugmaker said that this represents the first new
FDA-approved medicine for the condition in more than 20 years. The
approval is based on a phase 3 study of the drug that showed 75% of
patients administered the drug responded to treatment.
Hairy cell leukemia is a rare kind of slow-growing leukemia in
which the body produces an excess amount of lymphocytes.
Around 30% to 40% of patients with the disease who are treated
will relapse between five to 10 years, AstraZeneca said. The new
treatment was developed to meet this medical need.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
September 14, 2018 02:27 ET (06:27 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From May 2023 to May 2024